July - Summer Edition - CI Investments
July - Summer Edition - CI Investments
July - Summer Edition - CI Investments
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Commentary<br />
eBay and Wienerberger. Cash at the end of the quarter was<br />
about 4% of the fund, compared to just over 2% at the end of<br />
March and 5% at the beginning of the year.<br />
Castlerock International Equity Fund<br />
We have been selectively adding to our more cyclical holdings<br />
as we had cut them back one year ago. We are finding new<br />
investments in emerging markets and in technology. Our<br />
holdings in companies like Adidas, Glanbia and Galp<br />
Energia have done very well and our Japanese investments<br />
snapped back in value once investors determined that the<br />
tsunami would have little effect on their performance.<br />
What is truly ironic is that the best-performing areas of the<br />
world have been U.S. and European equities this year, proving<br />
that investors overlook and overreact regularly to bad news.<br />
One such area is Chinese equities. We have been looking<br />
at Chinese companies for a very long time (since 1994), yet<br />
we have just started to make commitments now. We seek out<br />
market share-leading companies with sustainable competitive<br />
advantages at reasonable prices that have established<br />
management teams who work for the shareholders. To get<br />
all of these characteristics in a Chinese company is tough.<br />
We have long been very skeptical of the internal allocation of<br />
capital within Chinese companies and also the accounting<br />
for their activities. With recent high-profile compliance<br />
problems, it is our judgment that the cleanup will be<br />
effective. We never doubt the internal drive of the Chinese<br />
business community to be world class in everything they do.<br />
It is their driving force. So we have invested in a Chinese<br />
clinical research company run by former executives from<br />
GSK-Wuxi Pharmatech.<br />
Castlerock Global Balanced Fund<br />
Castlerock Global Balanced Fund performed in line with the<br />
benchmark index for the six-month period. We experienced<br />
a notable loss in one holding – Irish Life – in the quarter as<br />
a desperate new government sought to distance itself from<br />
the previous government and rewrite the regulatory rules<br />
for banks and insurance holding companies. Although legal<br />
actions are underway, the losses have been taken.<br />
It is easy to feel despondent, but then we look at what is<br />
happening with the businesses we own in our focused<br />
international portfolio. Most are doing well, some exceedingly<br />
so. At a valuation level below the long-term global average,<br />
this should yield reasonably good equity results. But when,<br />
we just do not know. The reverse seems to be true in the<br />
fixed-income world. Investors seem to view risk in a binary<br />
fashion. That is, they love the government debt of a country<br />
and then they dump it in a lemming-like behaviour when<br />
they no longer agree that country is credit worthy. To this<br />
point, we have systematically lowered our fixed-income<br />
exposure to government securities as they have risen in price<br />
to the point where we see little long-term value. While it is<br />
costly in total rates of return, we have shortened our exposure<br />
to short-term government securities in wait for opportunities<br />
to buy quality corporate exposures at higher yields.<br />
It seems certain now that the pace of earnings growth will<br />
slow down from recovery levels to normal 4% to 6% levels.<br />
This slowdown has caught some investors off guard, most<br />
notably in the cyclical investment areas like emerging<br />
markets, commodities and cyclical stocks. We have felt<br />
a limited pullback in our portfolio, notably in our smaller<br />
Brazilian holdings and in our construction-oriented<br />
companies and semiconductor holdings.<br />
We have been selectively adding to our more cyclical holdings<br />
as we had cut them back one year ago. We are finding new<br />
investments in emerging markets and in technology. Our<br />
holdings in companies like Adidas, GlaxoSmithKline,<br />
Northrup Grumman, Glanbia, Affymetrix and Galp Energia<br />
have done very well. Our Japanese investments have also<br />
snapped back in value once investors determined that the<br />
tsunami had little effect on these companies.<br />
Director of Equities: Matias Galarce, Evelyn Huang<br />
SUMMER 2011 PERSPECTIVE AS AT JUNE 30, 2011 31